<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867280</url>
  </required_header>
  <id_info>
    <org_study_id>Sorafenib-MVI</org_study_id>
    <nct_id>NCT02867280</nct_id>
  </id_info>
  <brief_title>Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection</brief_title>
  <official_title>A Prospective Multicenter Non-randomized Controlled Study of Sorafenib (Nexavar) Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective multicenter non-randomized controlled study evaluates the efficacy and&#xD;
      safety of treatment with Sorafenib (Nevaxar) in patients with hepatocellular carcinoma with&#xD;
      microvascular invasion after radical resection compared to conventional therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicenter, non-randomized, open-label, blank controlled study which&#xD;
      initiated by Investigators. The study population include patients without macroscopic&#xD;
      vascular invasion and distant metastasis, undergoing R0 resection, postoperative pathology&#xD;
      confirming hepatocellular carcinoma with microvascular invasion (MVI) (BCLC A or B stage; T2&#xD;
      or part T3aN0M0). The primary end point of this study is recurrence free survival（RFS）at the&#xD;
      2nd postoperative years, and the secondary end points include postoperative median time to&#xD;
      recurrence (TTR), 1-year, 3-years, 5-years postoperative recurrence free survival (RFS),&#xD;
      3-years, 5-years postoperative overall survival, and safety and tolerance of sorafenib as an&#xD;
      adjuvant therapy for HCC. Patients in the treatment group will start Sorafenib within 4 weeks&#xD;
      after hepatectomy at doze of 400mg per day, and last continuously for 2 years, or until&#xD;
      disease progression. Patients in the control group will take regular treatment with no use of&#xD;
      Sorafenib. Both groups are forbid receiving postoperative anti-cancer therapy such as&#xD;
      adjuvant radiotherapy, chemotherapy and TACE. Patients of both groups should receive&#xD;
      antiviral therapy according to guidelines. Chinese traditional medicine and nutritional&#xD;
      support can be used without limitation, and the information of concomitant drug need to be&#xD;
      recorded for further analysis. Treatment for relieve drug related AEs can be used as needed.&#xD;
      Patients of both groups will be treated with best clinical practice as routine after&#xD;
      confirmed recurrence/metastasis, and the information of further treatment need to be recorded&#xD;
      and follow-up till death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Midterm analysis showed negative results.&#xD;
  </why_stopped>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the recurrence free survival rate at 2 years after hepatectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time To Recurrence</measure>
    <time_frame>From date of liver resection until the date of first documented relapse, assessed up to 5 years</time_frame>
    <description>To determine the median postoperative time to recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the recurrence rate within 2 years after hepatectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>1year, 3years, 5 years</time_frame>
    <description>To determine the recurrence free survival at postoperative 1-year, 3-year, and 5-year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years, 5 years</time_frame>
    <description>To determine the overall survival at postoperative 3-year and 5-year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-related Adverse Events measures using CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
    <description>measures using CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose modification of sorafenib due to adverse events.</measure>
    <time_frame>2 years</time_frame>
    <description>The actual total dose of sorafenib for every patients will be collected as well.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib (Nexavar) 200mg tablet, 2 tablets oral daily for 2 years, starting within 4weeks after hepatectomy. Regular treatment combined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No use of Sorafenib (Nexavar). Regular treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>red round tablet</description>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-75 years&#xD;
&#xD;
          2. Hepatocellular carcinoma confirmed by pathology&#xD;
&#xD;
          3. No macroscopic tumor thrombus vascular invasion and distant metastasis&#xD;
&#xD;
          4. R0 resection（clean resection margin both macroscopically and microscopically）&#xD;
&#xD;
          5. MVI confirmed by pathology&#xD;
&#xD;
          6. ECOG 0-1&#xD;
&#xD;
          7. Child-Pugh stage A&#xD;
&#xD;
          8. WBC &gt; 3×10E9/L；HB &gt; 90 G/L；PLT &gt; 50×10E9/L&#xD;
&#xD;
          9. ALT，AST not exceeding 5 times of the upper limit of normal value；CRE，TBIL not&#xD;
             exceeding 1.5 times of the upper limit of normal value&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tumor rupture or invading to adjacent organs&#xD;
&#xD;
          2. Patients who underwent liver transplantation&#xD;
&#xD;
          3. Past history of or simultaneously receiving other anti-cancer therapy (such as TACE,&#xD;
             chemotherapy, radiotherapy and others）and immune cell infusion therapy&#xD;
&#xD;
          4. Uncontrolled cardiovascular and cerebrovascular diseases&#xD;
&#xD;
          5. History of gastrointestinal bleeding within 6 months&#xD;
&#xD;
          6. Active infection other than HBV, HCV&#xD;
&#xD;
          7. Postoperative complications, not suitable to take Sorafenib (such as long term use of&#xD;
             drainage due to bile leakage, poor wound healing and others)&#xD;
&#xD;
          8. Confirmed liver cancer recurrence or metastasis within 4 weeks after hepatectomy&#xD;
&#xD;
          9. Poor compliance, cannot adhere to regular follow up&#xD;
&#xD;
         10. Diagnosed with other original malignant tumors other than HCC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minshan Chen, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>February 9, 2020</last_update_submitted>
  <last_update_submitted_qc>February 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Chen Min-Shan</investigator_full_name>
    <investigator_title>Director of the Department of Hepatobiliary Surgery</investigator_title>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>Microvascular invasion</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

